Rockwell Medical (RMTI) Research & Development (2010 - 2026)
Rockwell Medical (RMTI) posted Research & Development of $567000.0 for Q1 2026, up 5.0% on a QoQ basis from $540000.0 in Q4 2025, and down 20.25% year-over-year from $711000.0 in Q1 2025.
Rockwell Medical (RMTI) Research & Development (2010 - 2026) Analysis & Trends
Rockwell Medical's Research & Development history runs 17 years deep, the most recent figure standing at $567000.0 for Q1 2026.
- Quarterly Research & Development fell 20.25% year-over-year to $567000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 53.51% YoY) and the FY2025 annual result came in at $2.4 million, down 14.37% from the prior year.
- Research & Development was $567000.0 for Q1 2026 at Rockwell Medical, up from $540000.0 in the prior quarter.
- Across five years, Research & Development topped out at $2.7 million in Q4 2024 and bottomed at -$869000.0 in Q4 2022.
- A 5-year average of $564823.5 and a median of $531000.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 401.74% — and 2024, when it soared 1596.27%.
- Rockwell Medical's Research & Development stood at -$869000.0 in 2022, then surged by 118.53% to $161000.0 in 2023, then surged by 1596.27% to $2.7 million in 2024, then tumbled by 80.23% to $540000.0 in 2025, then climbed by 5.0% to $567000.0 in 2026.
- Business Quant data shows RMTI's Research & Development at $567000.0 in Q1 2026, $540000.0 in Q4 2025, and $531000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Rockwell Medical | 26.61 Mn | 2.72 Mn | 2.90 Mn | 567,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 540,000.00 |
| Sep 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 572,000.00 |
| Mar 31, 2025 | 711,000.00 |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 726,000.00 |
| Jun 30, 2024 | 586,000.00 |
| Mar 31, 2024 | 594,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Sep 30, 2023 | 494,000.00 |
| Jun 30, 2023 | 530,000.00 |
| Mar 31, 2023 | 278,000.00 |
| Dec 31, 2022 | -869,000.00 |
| Sep 30, 2022 | 469,000.00 |
| Jun 30, 2022 | 526,000.00 |
| Mar 31, 2022 | 455,000.00 |
| Dec 31, 2021 | 288,000.00 |
| Sep 30, 2021 | 1.54 Mn |
| Jun 30, 2021 | 2.42 Mn |